Senate confirms Crawford to lead FDA

Share this article:
The Senate acted last night to approve Dr. Lester Crawford's nomination as commissioner of the FDA. The vote, 78-16 in favor of the nomination, caps a months-long delay caused by a dispute over approval of the emergency contraceptive Plan B and an investigation into allegations that Crawford had an affair with a colleague.
"Dr. Crawford is a dedicated public servant who has ably led the agency over the last year and previously served as deputy commissioner," said Secretary of Health and Human Service Mike Leavitt. "I look forward to working with Dr. Crawford and FDA as we seek to continue advancing the nation's health."
Leavitt said last week that FDA would make a decision on switching Barr Laboratories' emergency contraceptive Plan B to OTC status by Sept. 1st.
Democratic Sens. Patty Murray of Washington and Hillary Clinton of New York then announced that they would lift a "hold" they had placed on Crawford's nomination, which had effectively prevented a vote.
The senators, however, said they continue to have "concerns about the lack of leadership and independent decision-making that Dr. Crawford and the FDA have shown in this case."
The nomination also was delayed several weeks by accusations that Crawford was carrying on an affair with someone in his office, but an investigation turned up no evidence.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.